Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.

about

Drug resistance and new therapies in colorectal cancer

P2860

Q58740344-8B3E0A06-FBB4-4505-AD32-C983DDC1EA30

P2860

Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.

Item

http://www.wikidata.org/entity/Q52362144

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Individualization of Irinoteca ...... ynamics, and Pharmacogenetics.

@en

Individualization of Irinoteca ...... ynamics, and Pharmacogenetics.

@nl

type

Item

label

Individualization of Irinoteca ...... ynamics, and Pharmacogenetics.

@en

Individualization of Irinoteca ...... ynamics, and Pharmacogenetics.

@nl

prefLabel

Individualization of Irinoteca ...... ynamics, and Pharmacogenetics.

@en

Individualization of Irinoteca ...... ynamics, and Pharmacogenetics.

@nl

P1476

Individualization of Irinoteca ...... dynamics, and Pharmacogenetics

@en

P2093

Femke M de Man

http://www.w3.org/2001/XMLSchema#string

Ron H J Mathijssen

http://www.w3.org/2001/XMLSchema#string

Ron H N van Schaik

http://www.w3.org/2001/XMLSchema#string

Sander Bins

http://www.w3.org/2001/XMLSchema#string

P2860

Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes

PharmGKB summary: very important pharmacogene information for UGT1A1

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

Comparison of first-line chemotherapy based on irinotecan or other drugs to treat non-small cell lung cancer in stage IIIB/IV: a systematic review and meta-analysis

Structural insights into CPT-11 activation by mammalian carboxylesterases

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue

P2888

s40262-018-0644-7

P304

1229-1254

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40262-018-0644-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Andrew K L Goey

P577

2018-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29520731

http://www.w3.org/2001/XMLSchema#string

P932

6132501

http://www.w3.org/2001/XMLSchema#string

Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.

about

P2860

P2860

Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932